ow-dose intravenous ketamine with haloperidol in reducing delirium and agitatio
Phase 3
- Conditions
- Condition 1: Delirium in elderly patients. Condition 2: Agitation in elderly patients.Delirium, not induced by alcohol and other psychoactive substancesR45.1Restlessness and agitation
- Registration Number
- IRCT20230522058252N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Age over 65 years and hospitalization in the intensive care unit
Richmond Agitation Sedation Score more equal to 2
Troponin and BNP not positive
Systolic pressure less than 140 mm Hg
Diastolic pressure less than 95
Heart rate less than 100
Exclusion Criteria
Dissatisfaction of the patient or the patient's guardian
Cardiovascular disease
History of psychosis
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reynolds and Richmond score less than one. Timepoint: At the beginning of the study (before the injection) and again at 5, 10, 15 minutes after the injection. Method of measurement: Reynolds and Richmond Score.
- Secondary Outcome Measures
Name Time Method The duration of reaching a Reynolds and Richmond score less than one. Timepoint: At the beginning of the study (before the injection) and again at 5, 10, 15 minutes after the injection. Method of measurement: Reynolds and Richmond Score.;Side effects. Timepoint: 60 minutes after the start of the intervention. Method of measurement: ECG to evaluate QT interval, blood pressure, heart rate, presence of seizures or hallucinations before and after receiving any of the drugs.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ketamine's anti-delirium effects in elderly ICU patients?
How does low-dose ketamine compare to haloperidol in managing ICU delirium and agitation?
Are there specific biomarkers that predict response to ketamine or haloperidol in ICU delirium?
What are the potential adverse events associated with low-dose ketamine in elderly ICU patients?
How do NMDA receptor antagonists like ketamine compare to antipsychotics in delirium management?